The field of 3D bioprinting is revolutionizing tissue engineering, regenerative medicine, and drug discovery. At the heart of this innovation are bioinks—the biomaterial formulations that allow for the deposition of living cells, growth factors, and extracellular matrices in controlled three-dimensional patterns.
In this post, we profile seven leading U.S.-based biomaterials engineering companies that are driving innovation in the design and fabrication of bioinks. These companies are not only shaping the future of human-compatible tissue manufacturing, but also expanding the commercial and clinical applications of bioprinting.
1. CELLINK (BICO Group) – U.S. Division
U.S. Location: Cambridge, MA
Parent Company: BICO (Sweden)
🔬 Main Product Line:
- BIO X™ Bioinks Series (e.g., GelMA, Collagen, Alginate, Fibrin)
- CELLINK LAMININK™, CELLINK GelXA™, CELLINK SKIN™, CELLINK BONE™
✅ Pros:
- Offers standardized, ready-to-print, cell-compatible bioinks optimized for various tissue types.
- Tunable mechanical properties, crosslinking options, and excellent print fidelity.
- Compatible with a wide range of cells (stem cells, fibroblasts, chondrocytes).
- Integrated workflows with CELLINK’s bioprinters and software.
📈 Future Growth Prospects:
CELLINK is expanding beyond R&D applications into preclinical models, organ-on-chip systems, and transplantable tissues. With a robust catalog and global distribution, CELLINK is a powerhouse in the commercialization of bioinks for bioprinting research and clinical-grade tissue fabrication.
2. Advanced BioMatrix (a BICO company)
Headquarters: San Diego, CA
🔬 Main Product Line:
- UltraPure™ Collagen, HyStem® Hydrogel Kits, PhotoGel® Gelatin Methacrylate (GelMA)
- Bioinks for soft tissue, cartilage, vasculature, and bone applications.
✅ Pros:
- Specializes in collagen-based bioinks, known for their biocompatibility and structural similarity to native ECM.
- PhotoGel® enables UV crosslinkable printing, ideal for layered structures.
- HyStem® system offers modular bioink building blocks for user-specific compositions.
📈 Future Growth Prospects:
By focusing on ECM-mimetic materials, Advanced BioMatrix is well-positioned to lead in custom tissue fabrication, especially for high-fidelity 3D cell culture and bioprinting. Its synergy with CELLINK’s broader platform enhances scalability and product diversity.
3. Allevi (3D Systems)
Headquarters: Philadelphia, PA
Parent Company: 3D Systems
🔬 Main Product Line:
- Allevi Bioinks Library: Fibrin, Alginate, Collagen, Gelatin, dECM (decellularized ECM-based bioinks)
- Tissue-specific bioinks for cartilage, liver, and skin.
✅ Pros:
- Offers plug-and-play compatibility with Allevi’s bioprinters.
- Includes bioinks for both soft and hard tissues, suitable for a variety of research applications.
- Decellularized ECM (dECM) bioinks mimic native tissue signaling for enhanced cell differentiation.
📈 Future Growth Prospects:
As part of 3D Systems, Allevi is integrating bioprinting into clinical R&D, pharmaceutical testing, and custom implant development. The dECM product line has enormous potential in personalized tissue therapeutics and disease modeling.
4. RegenHu (Now part of 3D Systems)
U.S. Offices: New York and Connecticut
Origin: Switzerland (acquired by 3D Systems)
🔬 Main Product Line:
- R-Gel™, R-Fibrinogen™, and R-Matrix™ series
- Customizable bioinks for neural, bone, and cardiovascular applications
✅ Pros:
- RegenHu’s bioinks are formulated to support multi-material and multi-cell printing.
- Extensive experience in hybrid biofabrication, combining biomaterials and cells with structural scaffolds.
- Integration with AI-driven biofabrication tools.
📈 Future Growth Prospects:
Now under 3D Systems’ umbrella, RegenHu is expanding toward scalable, GMP-compliant bioprinting for clinical-grade constructs, including vascularized tissues and implantable therapeutic tissues.
5. Aspect Biosystems (U.S. R&D Collaborations)
Main U.S. Collaborations: Houston, TX & Boston, MA
Headquarters: Vancouver, Canada
🔬 Main Product Line:
- Physiologically Relevant Bioinks – For liver, pancreas, and musculoskeletal applications
- Proprietary microfluidic-based bioprinting technology
✅ Pros:
- Known for tissue-specific bioinks combined with cell-laden microchannels, ideal for vascularized and perfusable constructs.
- Liver and pancreatic bioinks are particularly promising for diabetes and hepatic disease modeling.
- Collaborates with major U.S. institutions (JDRF, Novo Nordisk, and U.S. universities).
📈 Future Growth Prospects:
Aspect’s focus on transplantable tissues and cell therapy integration is paving the way toward bio-printed organ replacements. Its microfluidic precision enables unparalleled control in bioink formulation and tissue complexity.
6. Xylyx Bio
Headquarters: New York, NY
🔬 Main Product Line:
- ECMatrix™ Bioink – Derived from tissue-specific decellularized extracellular matrix
- Matrix-optimized substrates and coatings for enhanced cell function
✅ Pros:
- ECMatrix bioinks offer organ-specific biochemical cues, ideal for in vitro disease models and implantable grafts.
- Products are developed using human-derived ECM, providing more accurate environments for cell differentiation and function.
- Strong collaborations in oncology, nephrology, and cardiac tissue modeling.
📈 Future Growth Prospects:
As precision medicine grows, Xylyx’s organ-specific bioinks will find rising demand in pharmacokinetics, drug screening, and engineered autografts. Their expansion into multi-organoid models positions them for success in translational tissue engineering.
7. Humabiologics
Headquarters: Phoenix, AZ
🔬 Main Product Line:
- Human-derived Gelatin and Collagen Bioinks
- Designed for high cell viability and FDA-compatible translational research
✅ Pros:
- One of the few companies providing human-sourced, native biomaterials for bioink development.
- High-purity, xenogen-free collagen suitable for clinical bioprinting and scaffold fabrication.
- Bioinks are compatible with extrusion and inkjet bioprinters.
📈 Future Growth Prospects:
Humabiologics is bridging the gap between preclinical R&D and clinical-grade tissue manufacturing. Their regulatory-conscious sourcing and emphasis on native biochemistry make them attractive partners for FDA-regulated bioprinting applications.
🧠 Final Thoughts
Bioinks are more than just printing materials—they are living platforms that support, instruct, and transform cellular behavior. The companies highlighted above are tackling the most pressing challenges in bioprinting: vascularization, scalability, tissue specificity, and regulatory translation.
As applications expand from cosmetic tissue scaffolds and high-throughput drug screening to custom transplants and implantable organs, bioinks will define the success of 3D bioprinting in clinical medicine.
📬 Add Your Company to the Directory
If your company is innovating in bioink development, tissue printing, or regenerative scaffolds, we invite you to join our growing network. Submit your profile at BioMedEngineerDirectory.com and share your impact.
🎥 Watch Our YouTube Channel
Want to learn more about how bioinks are revolutionizing medicine?
Subscribe to our YouTube Channel for tutorials, lab walk-throughs, and interviews with industry leaders in bioprinting and tissue engineering.
📬 Have Questions or Ideas?
We’d love to hear from you! Whether you’re a student, educator, or industry professional, feel free to contact us with your questions, suggestions, or collaboration opportunities.
